Skip to main content
RLAY logo

RLAY · Relay Therapeutics, Inc.

Track RLAY — free
$16.12 +0.21 (+1.32%) At close · Nov 20
Market Cap
$3.56B
Shares
220.96M
Volume · Nov 20 3.98M Avg daily vol (3M) 2.93M

Price & Indicators

 

Key stats

Close
$16.12
Fri 20 Nov
Open
$15.59
Fri 20 Nov
Average volume, 30 days
2.5M
shares a session
Short interest
43.6M
19.7% of shares · 20.7 days to cover
Day range
$15.17$16.33
Open $15.59 Close $16.12
52-week closing range
$6.38$20.75
Close $16.12 22.3% under the high
Short volume, last session
62%
Last earnings
Nov 4, 2026
Latest filing
10-Q · Nov 4
Price history
Jul 2020 to Nov 2026

Up next

Feb 4, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 18
Investor event
Zovega Enters Three Pivotal Trials; Cash Runway Into 2029

Relay's CEO said its PI3K alpha mutant-selective asset, Zovega, is moving into three pivotal trials, including a second-line breast cancer trial expected to be fully enrolled by mid-2027. The company reported $849 million of cash, which should last well into 2029. Relay plans an update on vascular anomalies data at ASH in December.

4 source passages
We have Zovega, which is our PI3K alpha mutant selective asset, now moving forward, hopefully soon, in three pivotal trials. We announced a couple of weeks ago that we'll have this trial fully enrolled by the middle of 2027. and we have $849 million of cash. It should take us well into 2029. we will show data at ASH in December that will update the data that we We showed back in May Open the document at this passage
Nov 10
Investor event
ASH data on all 32 patients follows 60% response rate

Relay will present ASH data on all 32 patients from its dose randomization portion, after showing a 60% volumetric response rate across three doses at ISFA in May. Management models five and a half months of median PFS for CAPI. Pfizer supplies termociclib under a clinical trial supply agreement for a frontline trial due to start early next year.

4 source passages
At ASH, what we'll show is those 32 patients again, and we'll show now efficacy and safety data on all 32 patients. back in ISFA, we showed across those three doses a 60% volumetric response rate. there's enough data out there now that makes us confident to model five and a half months. We have a clinical trial supply agreement in place with Pfizer where they supply a termociclib, their selective CDK4 molecule, for our frontline trial that we're on track to start early next year. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash runway extends into 2029

Relay Therapeutics said cash, cash equivalents and investments of $848.6 million as of September 30, 2026 should fund operations into 2029. Nine-month net loss was $238.7 million, while zovegalisib received FDA Breakthrough Therapy designation with fulvestrant.

Net loss $81.75M Diluted EPS -$0.37
Read from the MD&A section
3 source passages
We believe our cash, cash equivalents, and investments of $848.6 million as of September 30, 2026 will enable us to fund our operating expenses and capital expenditure requirements into 2029. Our net losses were $238.7 million and $221.6 million for the nine months ended September 30, 2026 and 2025, respectively. In February 2026, we announced that the FDA granted Breakthrough Therapy designation to zovegalisib in combination with fulvestrant for the treatment of adults with PIK3CA mutant HR+/HER2- locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor. Open the document at this passage
Nov 4
Current report 8-K
Lirafugratinib wins FDA approval with $848.6 million cash

Relay Therapeutics reported full FDA approval of LYRFIGTU™ (lirafugratinib) for cholangiocarcinoma with FGFR2 fusion or other rearrangement, $848.6 million in cash and investments, and zovegalisib trial enrollment expected to complete in mid-2027.

Financial results
3 source passages
The FDA granted full approval for LYRFIGTU™ (lirafugratinib) as a treatment option for patients with cholangiocarcinoma (CCA) with FGFR2 fusion or other rearrangement. As of September 30, 2026, cash, cash equivalents and investments totaled $848.6 million, as compared to $910.9 million as of June 30, 2026. Complete enrollment of Phase 3 ReDiscover-2 trial in 2L breast cancer estimated in mid-2027 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$10.35M
Trailing 12 months
Net income (TTM)
−$293.63M
Trailing 12 months
Revenue growth YoY
+53.4%
Year over year
Operating margin
-3,094.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$124.18M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+27.5%
Year over year · more shares
Price change (1Y)
+152.7%
Trailing year
Short interest
19.7%
Latest settlement · 20.7 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26

TL;DR. Relay Therapeutics reported Q2 2026 results with progress across its zovegalisib program: selected the zovegalisib plus atirmociclib triplet as the go-forward 1L breast cancer regimen (Phase 3 expected to start early 2027), presented initial positive Phase 1/2 vascular anomalies data, and raised cash to approximately $911 million providing runway into 2029; R&D spend rose to $76.5M driving a wider net loss of $83.7M.

Bullish
  • + Selected zovegalisib + atirmociclib triplet for 1L breast cancer with Phase 3 expected to initiate early 2027, with Pfizer supplying atirmociclib while Relay retains full global rights to zovegalisib.
  • + Reported 44% ORR for the triplet in heavily pretreated (median 3L) HR+/HER2- breast cancer patients at unoptimized doses, with consistent safety profile.
  • + Presented initial positive Phase 1/2 ReInspire data in vascular anomalies with 60% volumetric response at 12 weeks, supporting potential chronic use.
  • + Cash position grew to approximately $911M (from $642.1M at March 31, 2026) following a $316M follow-on offering, expected to fund operations into 2029.
  • + 11-month PFS shown for the doublet in 2L HR+/HER2- breast cancer, viewed by management as meaningfully differentiated versus capivasertib's ~5.5 months, with Phase 3 ReDiscover-2 enrolling.
Bearish
  • − R&D expenses rose to $76.5M in Q2 2026 from $63.9M in Q2 2025, driving a wider net loss of $83.7M.
  • − Net loss widened to $83.7M in Q2 2026 from $70.4M in Q2 2025.
  • − Revenue declined to $0.4M in Q2 2026 from $0.7M in Q2 2025.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +2%
above
Price vs 50-day avg −11%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 68%
mid-range
Momentum
relative strength
Strong
1-month return −11%
trailing
6-month return +3%
trailing
YTD return +91%
this year
Relative strength +12%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $18 › 200d $16 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +32 funds added
Insider flow Distributing
Net -$83.3K over 90 days · 100% sells
Short interest Falling
19.75% of shares out · ▼ -0.9% MoM · 20.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
265 holders — near 3-yr high, broad support
Squeeze score 77
high risk · 0–100
Fundamentals
Strong
Revenue growth +53%
Y/Y
EPS growth +32%
Y/Y
Free cash flow $-235.9M
Balance sheet $84.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 66%
annualized · 1-yr
Max drawdown −28%
past year
ATR 6.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+2% Bullish
Price vs 50-day avg
−11% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
68% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $18 › 200d $16 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +32 funds added
Insider flow Distributing
Net -$83.3K over 90 days · 100% sells
Short interest Falling
19.75% of shares out · ▼ -0.9% MoM · 20.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
265 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6 Now $16 · 68% Range high $21
vs 200-day avg +2% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Gross proceeds from underwritten follow-on public offering $316M May 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RLAY
Relay Therapeutics, Inc.
this stock
$3.56B +90.5% +53.4% — 19.7%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
265
% held
114.5%
Net QoQ
+6.2M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
301
View
Short & Settlement
Short Interest Falling
Shares short
43.6M
Days to cover
20.7d
Change
-397.6K sh
View
Short Volume
Short vol %
62%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
5.3K
Value
$103.6K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
40.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$83.3K
Buyers / Sellers
0 / 3
Buyers Sellers
View
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Jul 12, 2023
View
Financials
Financials
Revenue (FY)
$15.4M
Net income (FY)
$-276.5M
EPS diluted
$-1.61
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
32

Relay's CEO said its PI3K alpha mutant-selective asset, Zovega, is moving into three pivotal trials, including a second-line breast cancer trial expected to be fully enrolled by mid-2027. The company reported $849 million of cash, which should last well into 2029. Relay plans an update on vascular anomalies data at ASH in December.

View
Proposed Sales
Value
$169.1K
Shares
10.3K
Filed
Nov 18, 2026
View
Exempt Offerings
Offering
$30.0M
Filed
Jan 10, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Relay Therapeutics Reports Third…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
RLAY -10.9% -11.3% +2.7% -12.2% +90.5%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -2.3% -2.1% +11.9% -3.4% +89.4%
Key facts CIK 1812364 CUSIP 75943R102 13F (30d) 276 filings 247 filers Visit website Investor relations